Biotechnology company Hyundai Bioscience (KOSDAQ:048410) on Wednesday announced plans to conduct a Phase 3 clinical trial for its oral COVID-19 treatment, Xafty, targeting high-risk patients with mild-to-moderate COVID-19.

The high-risk group includes those aged 60 and above, adults over 19 with underlying conditions such as diabetes, hypertension, cardiovascular disease, chronic heart and lung diseases, and immunocompromised individuals. These patients are at a higher risk of developing severe complications if infected with COVID-19.

Xafty has shown promising results in previous trials, particularly for high-risk groups. This new trial aims to address the urgent need for effective treatments for this vulnerable population, especially those unable to take Paxlovid due to drug interactions.

While maintaining the current process for emergency use authorisation for mild-to-moderate COVID-19 patients, Hyundai Bioscience will seek to expedite a Phase 3 trial exclusively for high-risk patients.